Compare YDDL & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YDDL | EDIT |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | Philippines | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.4M | 233.3M |
| IPO Year | 2025 | 2016 |
| Metric | YDDL | EDIT |
|---|---|---|
| Price | $5.05 | $2.46 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | 81.6K | ★ 1.6M |
| Earning Date | 11-17-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 310.92 | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $62,922,700.00 | $46,383,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.89 | ★ N/A |
| Revenue Growth | ★ 118.15 | N/A |
| 52 Week Low | $3.61 | $0.91 |
| 52 Week High | $8.89 | $4.54 |
| Indicator | YDDL | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 44.41 |
| Support Level | N/A | $2.09 |
| Resistance Level | N/A | $2.70 |
| Average True Range (ATR) | 0.00 | 0.17 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 0.00 | 59.84 |
One and one Green Technologies Inc is engaged in recycling, production, and trading of recycled scrap metals in the Republic of Philippines. The company process raw materials and generate final products that include copper alloy ingot, aluminum scrapes, plastic beads, and others. It provides economical and flexible solutions to the challenges of electronic waste, metal scrap and industrial recycling. By providing lower-cost alternatives for processing recycled materials, It is not only Contributing to environmental sustainability but also highlight its role as a modern and specialized recycling company.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.